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Abstract
Background: The role of the adipokines in the pathogenesis of aortic stenosis (AS) is not well estab-
lished. The aim was to evaluate the relationship between adipokines and clinical characteristics as well 
as echocardiographic indices and noninvasive markers of vascular remodeling in patients with severe 
AS with preserved ejection fraction (EF). 
Methods: Sixty-five patients (F/M: 38/27; age: 68.3 ± 9.0 years; body mass index [BMI]: 29.6 ± 4.3 
kg/m2) with severe AS with preserved EF: 33 patients with paradoxical low-flow low-gradient AS (PLFLG 
AS) and 32 patients with normal flow high-gradient AS (NFHG AS) were prospectively enrolled into the 
study. Twenty-four subjects (F/M: 14/10; age: 65.4 ± 8.7 years; BMI: 29.6 ± 4.3 kg/m2) who matched 
as to age, sex, BMI and coronary artery disease (CAD) constituted the control group (CG). Clinical data 
and markers of vascular remodeling were related to the serum adipokines.
Results: There were no differences in the adipokines concentrations in the AS/CG. Patients with AS 
and coexisting CAD were characterized by decreased serum adiponectin (9.9 ± 5.5 vs. 12.7 ± 5.8 μg/mL,  
p = 0.040) and leptin (8.3 ± 7.8 vs. 21.6 ± 17.1 ng/mL, p < 0.001) levels compared to subjects  
without CAD. There were no differences in the serum adipokines concentrations between patients with 
PLFLG AS and NFHG AS. Systemic hypertension, diabetes, hyperlipidemia or markers of vascular 
remodeling did not discriminate adipokines concentrations. Multivariate regression analysis indicated 
that age (F = 3.02; p = 0.015) and E/E’ index (F = 0.87, p = 0.032) were independent predictors of 
the adiponectin level in the AS group.
Conclusions: The presence of AS with preserved EF did not change the adipokine serum profile. Adi-
pokines levels were modified by coexisting atherosclerosis but not the typical cardiovascular risk factors 
or the hemodynamic type of AS. (Cardiol J 2019; 26, 5: 483–492)
Key words: echocardiography, aortic stenosis, atherosclerosis, adipokines,  
vascular remodeling
Introduction
Adipokines are involved in various inflamma-
tory and metabolic processes, including athero-
sclerosis, hypertension and dyslipidemia. Their 
standard panel includes adiponectin, leptin resistin 
and visfatin. 
Adiponectin has antiatherogenic and anti-
inflammatory effects on endothelial cells and mac-
rophages [1, 2], which are caused by an increase in 
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nitrix oxide (NO) production, a reduction of adhe-
sion molecules in the endothelial cells, inhibition 
of macrophages cytokine production and foam cell 
formation supression [3–5]. Clinical studies impli-
cate hypoadiponectinemia in the pathogenesis of 
diabetes mellitus (DM) type 2, arterial hyperten-
sion (HA), coronary artery disease (CAD) and left 
ventricular (LV) hypertrophy [6–9]. 
Leptin, in turn, may have an impact on car-
diac hypertrophy and may be associated with an 
increased cardiovascular risk as plasma leptin con-
centrations were shown to be elevated in patients 
with LV dysfunction and heart failure [10–12]. 
Resistin, which has primarily been suggested as 
a hormone that potentially links obesity to DM, was 
later proved to regulate the processes of the athero-
sclerosis and cardiovascular disease as well [13, 14].
Visfatin, which was originally described as 
a protein secreted by visceral fat that mimics 
insulin effects, turned out to have a relationship 
with cardiovascular diseases. It can promote foam 
cell formation and angiogenesis [15–17]. Elevated 
visfatin serum levels were found in patients with 
acute myocardial infarction [18]. 
Adipokines may thus be considered to be 
a network that influences metabolic states and has 
the potential to impact directly upon the metabolic 
homeostasis of a system. Their role in other patho-
logical cardiovascular conditions is not yet well 
known. Assuming that there are some similarities 
between the pathophysiology of calcific aortic valve 
(AV) disease (AVD) and atherosclerosis, those 
proteins may likewise play a potential role in its 
development. Moreover, in aortic stenosis (AS) 
with a low-gradient and preserved ejection frac-
tion (EF), a clinical profile of patients with a higher 
incidence of obesity, HA and increased peripheral 
vascular resistance may especially be associated 
with adipokines abnormalities [19, 20]. 
Thus, the aim of this study was to evaluate the 
relationship between adipokines and the clinical 
characteristics as well as echocardiographic indices 
and noninvasive markers of vascular remodeling in 
patients with severe AS with preserved EF.
Methods
Population
Sixty-five patients (F/M: 38/27; age: 68.3 ± 
± 9.0 years; body mass index [BMI]: 29.6 ± 4.3 kg/m2) 
with severe degenerative AS (New York Heart 
Association [NYHA] I/II/III: 20/37/8) with pre-
served LVEF (> 50%) (Table 1) — 33 patients with 
paradoxical low-flow/low-gradient AS (PLFLG AS) 
and 32 patients with normal flow/high-gradient AS 
(NFHG AS) were prospectively enrolled into the 
study. Twenty-four healthy subjects (F/M: 14/10; 
age: 65.4 ± 8.7 years; BMI: 29.6  ±4.3 kg/m2) who 
matched as to age, sex and BMI constituted the 
control group (CG). Clinical data, body composition, 
echocardiography, coronary angiography and non-
invasive markers of vascular remodeling were ex-
amined. The above data were related to the serum 
adiponectin, leptin, resistin and visfatin levels. The 
trial was conducted between 2011 and 2013 in the 
Departments of Cardiology and Cardiac Surgery at 
the Silesian Medical Center in Katowice and includ-
ed patients with severe AS and any symptoms that 
are related to AS. The exclusion criteria included 
actual indications for coronary revascularization, 
segmental wall motion abnormalities, a bad acous-
tic window (5 or more segments that could not be 
analyzed), non-sinus rhythm, a bicuspid AV, moder-
ate/severe mitral regurgitation, acute and chronic 
inflammatory diseases including myocarditis and 
endocarditis (in the 3 preceding months), NYHA IV, 
dilatation of the aortic root, Marfan syndrome, 
acute coronary syndromes, recurrent supraven-
tricular and ventricular arrhythmias, acute and 
chronic kidney disease (glomerular filtration rate 
< 60 mL/min/1.73 m2), malignancies, autoimmune 
diseases, immunosuppressive therapy, coexisting 
psychiatric or neurological disorders and alcohol or 
drug abuse. The study protocol was approved by 
the local Bioethics Committee. Each patient gave 
written consent to participate in the study.
Clinical data
The clinical characteristics of the patients in 
the study included their clinical status (NYHA/CCS 
class), anthropometric data (height, BMI, waist to 
hip ratio [WHR]), a physical examination and medi-
cal history (concomitant diseases, pharmacotherapy 
and smoking status). Body composition was deter-
mined by an impedance analysis using Bodystat.
Laboratory tests 
Blood samples (10 mL) were drawn from the 
peripheral vein from patients in the supine decubi-
tus position in the morning after an overnight fast. 
Total cholesterol, high- and low-density lipoprotein 
cholesterol fractions, triglycerides and creatinine 
serum concentrations were measured using rou-
tine methods. 
Serum levels of adipokines (intra-assay vari-
ability ranged: 6–9%) were measured using an en-
zyme-linked immunosorbent assay. A single-use kit 
was used in order to avoid inter-assay variability.
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Coronary angiography
Coronary angiography was performed in all 
patients. A diagnosis of CAD was established in 
cases of a ≥ 70% diameter narrowing in at least 
one of the three major epicardial coronary arteries.
Ultrasound assessment
Two-dimensional transthoracic echocardiog-
raphy was performed in all of the patients by an 
experienced sonographer according to guidelines 
of the European Society of Echocardiography [21]. 
An ultrasound system (GE Vivid 9) equipped with 
a 3.5–1.75 MHz transthoracic transducer was used 
for all of the patients. 
Left ventricular geometry and function
Two-dimensional M-mode echocardiography 
was used to measure LV dimensions in the left par-
asternal long-axis view. The LV end-diastolic diam-
eter (LVEDD), posterior wall (PW) and septal wall 
thickness (IVS) were measured at the end-diastole 
(d). The LV end-systolic diameter (LVESD) was 
also obtained. The LV mass (LVM) was calculated 
according to the following formula: LVM = 1.04 × 
× [(LVEDD + IVS + PW)3 – LVEDD3] – 13.6 and 
indexed for body surface area (BSA) to obtain the 
LVM index (LVMI). The values of LV end-diastolic 
(LVEDV) and end-systolic volume (LVESV) were 
measured using the Simpson method; LVEF, stroke 
volume (SV) and LV cardiac output (CO) were also 
obtained. The values of the LVM, SV and CO were 
indexed for body surface area (BSA).
Severity of aortic valve stenosis/effective 
orifice area of the implanted prosthesis
Maximal (Pmax) and mean (Pmean) trans-
valvular pressure gradients were obtained using 
a modified Bernoulli equation and the effective ori-
fice area (EOA) was measured using the continuity 
equation. The LV outflow tract (LVOT) dimension 
was measured three to four times and finally the 
mean LVOT value was used in the automatically 
calculated EOA. In order to avoid any mistakes, we 
compared EOA calculated by VTI and the Vmax and 
SV measured by Simpson’s formula and this was 
obtained using the Bernoulli equation. The values 
of the EOA were indexed for BSA. The valvuloar-
terial impedance (Zva) was calculated according to 
the recommended equation [21].
Noninvasive markers of vascular remodeling
Flow-mediated dilatation (FMD) 
The examinations were performed in the 
morning in a room at 22°C after a 15-min rest and 
an overnight fast. Smoking cigarettes was not al-
lowed for the previous 24 h. The subjects lay supine 
with their heads slightly extended. All of the meas-
urements of brachial arteries (BA) were performed 
above the antecubital fossa in the longitudinal plane 
using a sphygmomanometric cuff on the proximal 
portion of the arm. The right BA was scanned at 
rest, during reactive hyperemia and following the 
administration of sublingual nitroglycerin (0.5 mg). 
Reactive hyperemia was induced with the infla-
tion of a sphygmomanometer cuff to 200 mm Hg 
in order to occlude arterial inflow for 3 min. BA 
diameter (BAd) and blood flow were obtained 
during the 50–60 s after cuff deflation. Blood flow 
was measured from the pulsed Doppler signal and 
arterial diameters were taken from the anterior to 
the posterior “M” line at the end diastole. Images 
were acquired with electrocardiogram gating with 
the end of diastole corresponding to the onset of 
the R wave. The baseline and after-cuff deflation 
measurements were used for the FMD calculation 
(percent increase of the artery diameter compared 
to the baseline results) estimation. Endogenous 
vasodilatory capability, independent of BAd, was 
defined as the FMD × BAd index and calculated 
for allsubjects.
Pulse wave velocity (PWV) assessment 
Two pulse waves were obtained transcutane-
ously at the base of the neck for the right common 
carotid artery and over the right femoral artery. 
Transit time was measured as the time between 
the foot of the pulse wave and the foot of the 
R wave. Pulse transit time was determined as the 
average of 10 consecutive beats. Time delay (t) 
was calculated as the difference between these 
two transit times. The distance (d) traveled by 
the pulse wave was measured over the body 
surface as the distance between two recording 
sites. Pulse wave velocity was calculated as 
PWV = d (meters)/t (seconds).
Augmentation index (AIx)
The examination was performed using the 
applanation tonometry — Applanation (Sphygmo-
Cor system created by the Australian company 
AtCorMedical).
The test was performed in a lying position 
after a 5-min adaptation with the inner side of 
the hand facing upward. The tonometer head was 
placed on the wrist at the most palpable pulse. The 
system processed a registered pulse wave of the 
radial artery and marked the pulse curve in the 
ascending aorta. 
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The analyzed susceptibility of the vessels 
was defined by the following parameters: central 
systolic and diastolic blood pressure levels (aortic 
systolic and diastolic pressure), central pulse pres-
sure (aortic pulse pressure) and the value of the 
index gain (AIx).
Statistical analysis
Statistical analysis was performed using Med-
Calc for Windows, version 10.0. All of the text and 
table results are expressed as means ± standard 
deviation (SD) or as a number (percentage). The 
normal distribution result was analyzed using the 
Kolmogorov-Smirnov test. In the case of abnormal 
distribution, a logarithmic transformation was used.
The baseline clinical parameters and the 
results of the ancillary investigations were com-
pared using the two-sample t-tests for normal-
ly distributed continuous variables (Student’s 
t-test); in the case of an abnormal distribution, 
the Mann-Whitney U test was used. Categorical 
variables were compared using the c2 test. The 
Spearman rank-order test or Pearson correlations 
were used to determine the relationship between 
the variables. Multivariable linear regression was 
used to assess the independent predictors of the 
adipokine levels; parameters that were associated 
with plasma adipokines at the level of p < 0.1 on 
the univariate analysis were analyzed. A value of 
p < 0.05 was considered statistically significant.
Results
Clinical data
The clinical characteristics of AS patients and 
controls did not reveal any significant differences 
(Table 1).
There were no significant differences in 
LVESV, LVEDV, LVEF as well as in CO and the 
cardiac index (CI) between the patients with AS and 
the CG. LVMI was obviously significantly higher in 
the AS group (150.4 ± 32.6 vs. 115.2 ± 21.7 g/m2). 
Table 1. Characteristics of the study group and controls. 
Variable AS patients (n = 65) Controls (n = 24) P
Women/men 38 (58%) / 27 (42%) 14 (58%) / 10 (42%) 0.7
Age [years] 68.3 ± 9 69.1 ± 8.1 0.9
NYHA class I/II/III 20 (31%) / 37 (57%) / 8 (12%) 6 (25%) / 17 (71%) / 1 (4%) 0.9
CCS class 0/1/2/3 15 (23%) / 20 (31%) / 28 (43%) / 2 (3%) 4 (17%) / 8 (33%) / 12 (50%) / 0 0.9
Height [cm] 164 ± 10 165 ± 11 0.9
Weight [kg] 78.0 ± 13.7 77.1 ± 14.1 0.9
BMI [kg/m2] 29.6 ± 4.3 28.3 ± 4.3 0.5
BSA [m2] 1.87 ± 0.21 1.86 ± 0.22 0.9
WHR [cm] 0.93 ± 0.1 0.92 ± 0.06 0.9
Body fat (%] 33.1 ± 2.8 32.8 ± 3.1 0.8
Heart rate [bpm] 68.0 ± 10.4 67.3 ± 8.1 0.9
Systolic BP [mmHg] 127.1 ± 21.7 124.2 ± 17.8 0.9
Diastolic BP [mmHg] 82.6 ± 12.1 74.5 ± 7.4 0.7
Coronary artery disease 26 (40%) 12 (50%) 0.7
Hypertension 53 (82%) 17 (71%) 0.8
Diabetes 16 (25%) 8 (33%) 0.7
Current smoking 6 (9%) 4 (17%) 0.7
Smoking history 12 (18%) 7 (29%) 0.7
Triglycerides [mg/dL] 138 ± 48 142 ± 55 0.7
Total cholesterol [mg/dL] 188 ± 51 184 ± 47 0.8
HDL cholesterol [mg/dL] 45 ± 12 48 ± 14 0.8
LDL cholesterol [mg/dL] 112 ± 38 117 ± 37 0.9
Glomerular filtration rate [mL/min] 87.8 ± 12.3 89.6 ± 8.3 0.9
Data are presented as the mean ± standard deviation or number (percentage); AS — aortic stenosis; BMI — body mass index; BSA — body 
surface area; BP — blood pressure; CCS — Canadian Cardiovascular Society grading of angina pectoris; HDL — high-density lipoprotein cho-
lesterol; LDL — low-density lipoprotein cholesterol; NYHA — New York Heart Association functional classification; WHR — waist-to-hip ratio
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The AV annulus was significantly smaller in the AS 
group (21.5 ± 1.9 vs. 22.9 ± 2.1 mm, p = 0.013). 
The mean maximum AV gradient (Pmax) in the 
AS group was 95.8 ± 24.7 mmHg while the mean 
gradient (Pmean) was 58.6 ± 16.6 mmHg. The 
indexed EOA was calculated for 0.37 ± 0.08 cm2/ 
/m2 in the AS group (Table 2).
There were no significant differences ob-
served in the FMD value between the AS and the 
CG. There were also no differences in the BAd. 
However, the FMD × BAd index remained signifi-
cantly higher in the CG.
There were also no significant differences in 
the PWV between the two examined groups. Aortic 
systolic, diastolic pressure and pulse were insig-
nificantly higher in the CG. Value of the index and 
the gain remained same in both groups (Table 3).
Clinical data — PLFLG AS vs. NFHG AS
The mean age of both groups remained simi-
lar (68.5 ± 7.9 for PLFLG AS vs. 68.1 ± 10.2 for 
NFHG AS) as well as BMI (29.48 ± 4.2 vs. 29.8 ± 
± 4.6 kg/m2), WHR (0.9 ± 0.1 vs. 0.9 ± 0.1), 
systolic (133.9 ± 22.6 vs. 140.3 ± 20.5 mmHg) 
and diastolic (82.9 ± 12.3 vs. 82.3 ± 12.1 mmHg) 
blood pressure.
There were significant differences between 
the PLFLG AS and NFHG AS groups in CO (3.7 ± 
± 0.8 vs. 5.6 ± 1.6 L/min, p < 0.001) and CI (2.1 ± 
± 0.4 vs. 2.9 ± 0.6 L/min/m2, p < 0.001), LVMI 
(153.2 ± 26.7 vs. 136.1 ± 31.2 g/m2, p = 0.032) 
and Zva (6.2 ± 1.2 vs. 4.8 ± 0.9 mmHg/mL/m2, 
p < 0.001). Differences were observed in Pmean 
values, which were significantly lower in the PLFLG 
AS group (51.1 ± 16.9 vs. 60.4 ± 16.3 mmHg, 
Table 2. Results of transthoracic echocardiography in the study group and controls.
Variable AS patients (n = 65) Controls (n = 24) P
LVESV [mL] 47.0 ± 19.1 47.8 ± 17.1 0.92
LVEDV [mL] 115.9 ± 32.6 118.4 ± 39.1 0.91
LVEF [%] 60.5 ± 6.5 60.4 ± 6.4 0.95
CO [L/min] 4.4 ± 1.2 4.8 ± 1.7 0.87
CI [L/min/m2] 2.7 ± 0.7 2.8 ± 0.8 0.91
LVMI [g/m2] 150.4 ± 32.6 115.2 ± 21.7 0.009
AV anulus [mm] 21.5 ± 1.9 22.9 ± 2.1 0.013
Pmax [mmHg] 95.8 ± 24.7 – –
Pmean [mmHg] 58.6 ± 16.6 – –
iEOA [cm2/m2] 0.37 ± 0.08 – –
Zva [mmHg/mL/m2] 5.6 ± 1.1 – –
Data are presented as the mean ± standard deviation; AS — aortic stenosis; AV — aortic valve; CO — cardiac output; iEOA — indexed effec-
tive orifice area; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular end-systolic 
volume; LVMI — left ventricular mass index; Pmax — maximum gradient across aortic valve; Pmean — mean gradient across aortic valve; 
Zva — valvuloarterial impedance
Table 3. Baseline vascular parameters of the study groups.
AS patients (n = 65) Controls (n = 24) P
FMD [%] 11.57 ± 5.8 13.22 ± 5.2 0.205
BAd [mm] 3.46 ± 0.5 3.58 ± 0.6 0.799
FMD × BAd 36.28 ± 8.5 43.51 ± 9.8 0.043
PWV [m/s] 9.9 ± 2.7 7.8 ± 3.2 0.089
Aortic SP [mmHg] 123.2 ± 10.5 131.2 ± 11.2 0.744
Aortic DP [mmHg] 69.3 ± 15.2 72.5 ± 11.6 0.804
AP [mmHg] 49 ± 14.1 56.4 ± 12.3 0.462
AIx [%] 33.0 ± 12.8 33.0 ± 12.8 0.281
Data are presented as the mean ± standard deviation; AS — aortic stenosis; AIx — augmentation index; AP — arterial pressure; BAd — brachial 
artery diameter; DP — diastolic pressure; FMD — flow-mediated dilatation; PWV — pulse wave velocity; SP — systolic pressure
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p = 0.02). The mean values of AV annulus, Pmax 
and iEOA were similar.
There were no noticeable differences in PWV 
(7.5 ± 3.3 vs. 6.5 ± 2 m/s) and in FMD (15.3 ± 11 
vs. 18.6 ± 10%).
No significant differences were observed be-
tween all adipokine levels in patients with PLFLG 
AS vs. NFHG AS.
Serum adipokines levels in the study  
group and controls 
There were no significant differences in the 
serum adiponectin, leptin, visfatin and resistin 
concentrations in the AS and CG (Table 4). 
Serum adipokines levels in the study group 
regarding clinical characteristics 
Patients with AS and co-existing CAD were 
characterized by decreased serum adiponectin (9.9 ± 
± 5.5 vs. 12.7 ± 5.8 μg/mL, p = 0.040) and leptin 
(8.3 ± 7.8 vs. 21.6 ± 17.1 ng/mL, p < 0.001) levels 
compared to subjects without CAD. There were 
no significant differences in visfatin (2.4 ± 2.0 vs. 
3.3 ± 2.4 ng/mL, p = 0.074) and resistin levels 
(5.00 ± 4.2 vs. 7.28 ± 6.1 ng/mL, p = 0.102) (Table 5).
There were no significant differences in serum 
adipokines concentrations between patients with 
concomitant HA. Patients with AS and DM had an 
insignificantly lower adiponectin level (10 ± 5.9 vs. 
12.26 ± 5.6, p = 0.052 μg/mL) (Table 5).
There were also no significant differences 
in the serum adipokine concentrations between 
patients with PLFLG AS and NFHG AS (Table 5). 
Regression analysis
The adiponectin levels correlated with age 
(r = 0.464, p < 0.001), BMI (r = –0.334, p = 
= 0.006), body fat percentage (r = –0.315, p = 0.011), 
LVMI (r = –0.256, p = 0.039), LV SVi (r = –0.327, 
p = 0.008) and the E/E’ index (r = –0.268, 
p = 0.022) (Table 6). 
Leptin levels correlated with BMI (r = 0.456, 
p < 0.001), body fat percentage (r = 0.522, 
p < 0.001) and iEOA (r = –0.290, p = 0.019) (Table 6).
Multivariate regression analysis indicated 
age (F = 3.02; p = 0.015) and the E/E’ index 
(F = 0.87, p = 0.032) as independent predictors of 
the adiponectin level in the AS group.
Discussion
In the population with AS with preserved EF, 
some clinical and metabolic indices may play a piv-
otal role for the progression of the disease and its 
symptomatology. This is why the serum adipokines 
concentrations were compared between AS pa-
tients and the controls — there were no differences 
observed. Moreover, the hypothesis that the CAD, 
HA, DM, vascular parameters influenced the adi-
pokine serum levels was verified. This verification 
was a negative value in regard to the HA, DM and 
vascular indices. Patients with AS and co-existing 
CAD were characterized by decreased adiponectin 
and leptin levels compared to the subjects without 
CAD. This is an important finding of the study, es-
pecially that low serum levels of adiponectin have 
been recognized as a risk factor for atherosclerotic 
disease [22]. It should be noted that the protective 
mechanism of adiponectin, which has an influence on 
the progression of atherosclerosis and is associated 
with increasing apolipoprotein A1 and high-density 
lipoprotein cholesterol, which have beneficial effects 
on lipid metabolism [23].
When discussing the role of adiponectin in 
AS patients, we may take into account the data 
that describes the adiponectin levels in non-AS 
patients. In the literature, there are mainly data on 
adiponectin levels in patients with CAD [24, 25] or 
metabolic disorders [26] but limited data on the role 
of adiponectin in AS pathogenesis. Low adiponectin 
concentrations are well documented in patients with 
CAD [24]. Low adiponectin contributes to coronary 
plaque vulnerability [25]. In this study, patients 
with AS and co-existing CAD were characterized 
by decreased serum adiponectin and leptin levels 
compared to subjects without CAD. It was suspected 
that the same CAD-related mechanism of hypoadi-
ponectinemia was present in the presented group.
Table 4. Serum adipokines levels in the study group and controls.
AS patients (n = 65) Controls (n = 24) P
Adiponectin [μg/mL] 11.57 ± 5.8 11.59 ± 4.2 0.674
Leptin [ng/mL] 16.28 ± 13.5 21.51 ± 19.8 0.44
Visfatin [ng/mL] 2.93 ± 2.2 2.80 ± 2.2 0.734
Resistin [ng/mL] 6.37 ± 5.5 7.13 ± 4.6 0.281
Data are presented as the mean ± standard deviation; AS — aortic stenosis
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The available data on the role of adipokines 
in AS are limited to some problems. Recently, 
Gucuk Ipek et al. [27] showed, similar to the present 
findings, that there is no relationship between the 
adiponectin levels and calcific AVD. In contrast, 
Kolasa-Trela et al. [28] published an article suggest-
ing that adipokines may be involved in the progres-
sion of AS. In 2010, Mohty et al. [29] observed that 
older patients with AS had a higher plasma level 
of resistin, which was associated with the degree 
of valvular calcification and inflammation. In their 
next paper, they showed that adiponectin may play 
a protective role against the inflammatory process and 
progression of calcific AVD [30]. They hypothesized 
that adiponectin might be partly responsible for the 
association between metabolic syndrome and calcific 
AVD. Concentrations of adiponectin were persis-
tently reduced in patients with metabolic syndrome 
and this was the first demonstration of its negative 
association with the progression of AS. This obser-
vation is in accordance with the present findings 
and from a practical point of view — the reduced 
circulating level of adiponectin may be associated 
with a more rapid progression of AS stenosis and 
enhanced valvular inflammation.
The next step of analysis involved the hemody-
namic profiles of patients with AS and preserved EF. 
Table 5. Serum adipokines levels in the study group regarding clinical characteristic.
Coronary artery disease (CAD) CAD (+) CAD (–) P
Adiponectin [μg/mL] 9.87 ± 5.5 12.7 ± 5.8 0.040
Leptin [ng/mL] 8.34 ± 7.8 21.56 ± 17.1 0.001
Visfatin [ng/mL] 2.38 ± 2.0 3.31 ± 2.4 0.074
Resistin [ng/mL] 5.00 ± 4.2 7.28 ± 6.1 0.102
Arterial hypertension (AH) HA (+) HA (–) P
Adiponectin [μg/mL] 11.64 ± 5.8 11.26 ± 5.9 0.754
Leptin [ng/mL] 16.35 ± 15.3 15.95 ± 13.9 0.741
Visfatin [ng/mL] 2.99 ± 2.1 2.70 ± 2.1 0.227
Resistin [ng/mL] 6.40 ± 5.4 6.23 ± 6.1 0.750
Diabetes mellitus (DM) DM (+) DM (–) P
Adiponectin [μg/mL] 9.95 ± 5.9 12.26 ± 5.6 0.052
Leptin [ng/mL] 10.62 ± 8.9 18.13 ± 16.9 0.183
Visfatin [ng/mL] 2.87 ± 2.4 2.96 ± 2.2 0.957
Resistin [ng/mL] 7.53 ± 6.7 5.99 ± 4.6 0.654
Stroke volume index (SVi) SVi < 35 mL/m2 (PLFLG AS) SVi ≥ 35 mL/m2 (NFHG AS) P
Adiponectin [μg/mL] 12.19 ± 5.4 10.92 ± 6.2 0.259
Leptin [ng/mL] 17.50 ± 14.1 15.02 ± 6.9 0.311
Visfatin [ng/mL] 3.09 ± 2.4 1.78 ± 2.1 0.507
Resistin [ng/mL] 6.76 ± 4.6 5.96 ± 3.9 0.718
Data are presented as the mean ± standard deviation; PLFLG AS — paradoxical low-flow low-gradient aortic stenosis; NFHG AS — normal flow 
high gradient aortic stenosis
Table 6. Regression analysis in the study group 
with adipokines as dependent variables.
Correlation 
coefficient
P
Adiponectin
Age 0.464 < 0.001
Body mass index –0.334 0.006
Body fat% –0.315 0.011
Left ventricular mass index –0.256 0.039
Stroke volume index –0.327 0.008
E/E’ –0.268 0.022
Leptin
Bod mass index 0.456 < 0.001
Body fat% 0.522 < 0.001
Indexed effective orifice area –0.290 0.019
Resistin
Pulse wave velocity 0.269 0.033
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Well-documented literature data as well as 
our previous findings indicated differences in 
demographics, the frequency of concomitant dis-
ease and systemic vascular resistance between 
populations with NFHG and PLFLG AS. Patients 
with PLFLG AS are characterized by a higher 
frequency of females, HA, LV hyperthrophy, in-
creased systemic vascular resistance and finally 
lower SVi [19, 20]. Although our subpopulation 
with PLFLG AS had a limited number of patients, 
it was representative of the above-mentioned 
characteristics. Regardless of different clinical 
characteristics of NFHG and PLFLG patients, 
there were no differences in adipokines concen-
trations in these groups. 
Adiponectin, and also leptin concentrations, 
correlated with standard obesity indices (BMI, 
body fat%). This observation is in concordance 
with previous data. It was demonstrated that low-
level adiponectin subjects were characterized by 
a significantly higher prevalence of some cardio-
metabolic comorbidities (obesity, visceral obesity, 
DM, insulin resistance, LV hypertrophy, metabolic 
syndrome, CAD) [26, 31, 32].
Interesting relationships were observed with 
regard to the adiponectin levels. Adiponectin lev-
els correlated positively with age and negatively 
with BMI, body fat, LVMI, SVi and the E/E’ index. 
Multivariate regression analysis confirmed that age 
and the E/E’ index were independent predictors of 
the adiponectin level in the AS group. Thus, the di-
astolic dysfunction that is typical for AS influenced 
adiponectin concentration.
Stojanovic et al. [31], similar to the present 
findings, found that adiponectin levels correlated 
with age, BMI and the E/E’ index in patients with 
metabolic syndrome and/or CAD. On the other hand, 
in patients with hypertrophic cardiomyopathy, 
plasma adiponectin levels were associated with an 
impaired LV systolic function but only slightly with 
E/E’ index [33]. 
Positive correlations were found in leptin 
levels with BMI and body fat%. Generally, leptin, 
which is a mediator of the long-term regulation 
of energy balance, suppresses food intake [34]. 
Subjects with high plasma leptin levels have 
a better prognosis, thus suggesting a protective 
role of leptin in overweight/mild obesity [35]. 
On the other hand, overweight and obesity are 
associated with hyperleptinemia secondary to an 
impaired sensitivity of leptin receptors [36]. Re-
cently, Karmazyn et al. [37] concluded that leptin is 
a cardiac hypertrophic factor and hyperleptinemia 
is associated with cardiovascular risk, especially 
as it pertains to heart failure. This can be of im-
portance in regards to AS-mediated hypertrophy 
and/or CAD. As presented above, the presented 
subjects with AS and CAD were characterized 
by increased serum leptin levels compared to AS 
patients without CAD. Further studies are needed 
to evaluate these interesting concepts. 
Regarding adipokines levels, it should also be 
taken into account the specificity of the population 
herein — relatively older subjects with AS. Schautz 
et al. [38] concluded that age-related changes in 
leptin and adiponectin levels are opposed to each 
other and are partly independent of adiposity and 
body fat distribution. 
Limitations of the study
A limitation of the current study could be the 
relatively small number of patients. It should be 
stressed, however, that the study was conducted 
in a prospective fashion, which undoubtedly rep-
resents its methodological strength. It is also 
agreed that the division of the AS cohort into the 
subgroups PLFLG AS and NFHG AS had limita-
tions related to the number of subjects. However, 
a well-known PLFLG AS clinical characteristic 
suggested an abnormal adipokine profile compared 
to NFHG AS. 
An echocardiographic evaluation, especially in 
older, obese patients, has limitations regarding the 
LVOT measurements, and finally the AS severity 
calculation. These problems were apparent, this 
is why all echocardiographic measurements were 
done very precisely by an experienced sonogra-
pher. Vascular response to sublingual nitroglycerin 
was not assessed because of the severity of AS. 
Moreover, adipokines levels were measured at 
one point only.
Conclusions
Severe degenerative AS with preserved EF is 
not associated with any change in the adipokine se-
rum profile. Adipokines serum levels are modified 
by co-existing atherosclerosis but not the typical 
cardiovascular risk factors or the hemodynamic 
type of AS. The adiponectin serum level in patients 
with severe AS with preserved EF is related to age 
and LV diastolic dysfunction.
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